Pfizer Stock News

Is your portfolio getting thinned out by all the profit-taking that tends to materialize when the market reaches record highs? That's OK.

Pfizer stock currently trades at very low volatility. That could mean it's ripe for a breakout trade, like a long strangle.

I remain bearish on Pfizer due to pricing pressures from IRA/340B and a looming 2026 patent cliff, despite Q2 2025 earnings beat. Cost-cutting measures have lifted EPS above expectations and could deliver $7.7B in savings by 2027, but in my view, these are not a substitute for topline growth. IRA Part D redesign and 340B discounts are already pressuring sales (e.g., Nurtec flat yoy despite 47% ...

Pfizer offers an attractive near-7% dividend yield, appealing for income-focused investors. Despite recent stagnation, Pfizer has consistently maintained its dividend payout and remains undervalued. The company has a number of exciting drugs ramping up sales to cover the loss of exclusivity risks, and revenue has grown YoY.

What's better than a stock that pays great dividends? How about one that's also a bargain?

Finding a high-yielding stock that is safe to hang on to can be a rarity. When yields get high (e.g.

If you're looking to boost your passive income stream with dividend-paying stocks, there's a tough dilemma that we all face. Stocks that offer high yields generally do so because their dividend payouts aren't growing very fast or at all.

Dividend stocks are a great investment choice for many reasons. Buying on the dip is even better, provided, of course, they have the means to bounce back.